<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967589</url>
  </required_header>
  <id_info>
    <org_study_id>NN9926-3950</org_study_id>
    <secondary_id>2012-002893-30</secondary_id>
    <secondary_id>U1111-1131-8724</secondary_id>
    <nct_id>NCT01967589</nct_id>
  </id_info>
  <brief_title>Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects</brief_title>
  <official_title>Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate safety,
      tolerability, pharmacokinetics (the exposure of the trial drug in the body) and
      pharmacodynamics (the effect of the investigated drug on the body) of multiple doses of a
      long acting GLP-1 analogue (NNC0113-0987) in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs) recorded</measure>
    <time_frame>From the time of first dosing (Day 0) and until completion of the post-treatment follow-up visit (Day 83âˆ’97)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the NNC0113-0987 plasma concentration curve</measure>
    <time_frame>During a dosing interval (0-24 hours) at steady state (Day 67; Day 68 and Day 69)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed NNC0113-0987 plasma concentration</measure>
    <time_frame>During a dosing interval (0-24 hours) at steady state (Day 67; Day 68 and Day 69)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed NNC0113-0987 plasma concentration</measure>
    <time_frame>During a dosing interval (0-24 hours) at steady state (Day 67; Day 68 and Day 69)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>From baseline (Day 0, pre-dose) to after 10 weeks of treatment (Day 70)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C (glycosylated haemoglobin)</measure>
    <time_frame>From baseline (Day 0, pre-dose) to after 10 weeks of treatment (Day 70)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From baseline (Day -1) to after 10 weeks of treatment (Day 70)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DC (dosing condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design. Planned end-dose is 5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design. Planned end-dose is 10 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design. Planned end-dose is 20 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0113-0987</intervention_name>
    <description>Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation</description>
    <arm_group_label>DC (dosing condition)</arm_group_label>
    <arm_group_label>Oral A</arm_group_label>
    <arm_group_label>Oral B</arm_group_label>
    <arm_group_label>Oral C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Once-daily doses for oral administration</description>
    <arm_group_label>DC (dosing condition)</arm_group_label>
    <arm_group_label>Oral A</arm_group_label>
    <arm_group_label>Oral B</arm_group_label>
    <arm_group_label>Oral C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, who is considered to be generally healthy, based on the medical history,
             physical examination and the results of vital signs, electrocardiogram (ECG) and
             laboratory safety tests performed during the screening visit, as judged by the
             investigator

          -  Age 18-64 years (both inclusive) at the time of signing informed consent

          -  BMI (body mass index) 20.0-29.9 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  History of, or presence of, cancer, diabetes or any clinically significant
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal (GI),
             endocrinological, haematological, dermatological, venereal, neurological, psychiatric
             diseases or other major disorders, as judged by the investigator

          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine
             neoplasia type 2

          -  History of chronic pancreatitis or idiopathic acute pancreatitis

          -  Use of prescription or non-prescription medicinal and herbal products (except routine
             vitamins) within three weeks preceding the dosing period. Occasional use of
             paracetamol or acetylsalicylic acid is permitted

          -  Subject with previous GI surgery, except subjects that underwent uncomplicated
             surgical procedures such as appendectomy, hernia surgery, biopsies, as well as colonic
             and gastric endoscopy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <last_update_submitted>June 19, 2014</last_update_submitted>
  <last_update_submitted_qc>June 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

